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Abstract
Bone formation is a complex developmental process involving the differentiation of mesenchymal stem cells to 
osteoblasts. Osteoblast differentiation occurs through a multi-step molecular pathway regulated by different 
transcription factors and signaling proteins. Osx (also known as Sp7) is the only osteoblast-specific transcriptional factor 
identified so far which is required for osteoblast differentiation and bone formation. Osx knock-out mice lack bone 
completely and cartilage is normal. This opens a new window to the whole research field of bone formation. Osx 
inhibits Wnt pathway signaling, a possible mechanism for Osx to inhibit osteoblast proliferation. These reports 
demonstrate that Osx is the master gene that controls osteoblast lineage commitment and the subsequent osteoblast 
proliferation and differentiation. This review is to highlight recent progress in understanding the molecular 
mechanisms of transcriptional regulation of bone formation by Osx.
Introduction
Bone formation takes place through two distinct pro-
cesses: endochondral ossification involving a cartilage
model and intramembranous ossification by which bones
form directly from condensations of mesenchymal cells
without a cartilage intermediate. Bone formation is a
highly regulated process involving the differentiation of
mesenchymal stem cells to osteoblasts. Osteoblasts pro-
duce a characteristic extracellular collagenous matrix that
subsequently becomes mineralized after hydroxyapatite
crystals deposition. Much progress has been made in
understanding the factors that control the gene expres-
sion program through the osteoblast induction, prolifera-
tion, differentiation, and maturation. Osteoblast
differentiation occurs through a multistep molecular
pathway regulated by different transcription factors and
signaling proteins (Table 1). Indian hedgehog (Ihh) is
required for endochondral but not for intramembranous
bone formation [1] and is needed for the establishment of
the osteogenic portion of the perichondrium/periosteum
and for the initial activation of the gene for Runx2. Runx2
is needed for the formation of both endochondral and
membranous skeletal elements. In Runx2-null mutants,
no endochondral and no membranous bones form [2].
Runx2 is required for the differentiation of mesenchymal
cells into preosteoblasts. As a downstream gene of
Runx2, Osx is required for the differentiation of preosteo-
blasts into mature osteoblasts. Osx is specifically
expressed in all osteoblasts. In Osx-null embryos, carti-
lage is formed normally, but the embryos completely lack
bone formation [3]. Wnt signaling is also essential to
osteoblast differentiation during embryonic develop-
ment. Conditional inactivation of β-catenin in either skel-
etal progenitor cells or at a later stage of osteoblast
development in mouse embryos blocks osteoblast differ-
entiation [4-7]. Other transcription factors involved in
osteoblast differentiation include Twist1, ATF4, SatB2,
Shn3, and Dlx5 [8-12]. This review focuses mainly on the
molecular mechanisms of transcriptional regulation of
bone formation by Osx.
Osx is an osteoblast-specific transcription factor
Osx was discovered as a bone morphogenic protein-2
(BMP2) induced gene in mouse pluripotent mesenchymal
cells, encoding a transcription factor that is highly spe-
cific to osteoblasts [3]. Osx is also expressed at low level
in pre-hypertrophic chondrocytes. The Osx gene is
located in chromosome 15 in mouse and in chromosome
12 in human. There are only two exons in the Osx gene.
Exon 1 sequence encodes the seven N-terminal amino
acids of Osx, and exon 2 contains the remaining open
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protein is a 428 amino acid polypeptide with a molecular
mass of about 46 kDa as shown in Figure1. The DNA-
binding domain of Osx is located at its C terminus and
contains three C2H2-type zinc finger domains that share
a high degree of identity with a similar motif in Sp1, Sp3,
and Sp4. There is a proline-rich region (PRR) close to the
N-terminus. Osx binds to functional GC-rich sequences
similar to the consensus binding sites of erythroid Krüpp-
el-like factor (EKLF) and Sp1. The subcellular localiza-
tion of Osx is restricted to the nucleus. The PRR region is
responsible for the Osx inhibitory effect on the Wnt sig-
naling pathway [13].
During mouse embryogenesis, Osx transcripts are not
detected before embryonic stage E13 [3]. Osx first
appears in differentiating chondrocytes, the surrounding
perichondrium, and mesenchymal condensations of
future membranous bones of E13.5 embryos. After E15.5,
Osx is strongly expressed in cells that are associated with
all bone trabeculae and bone collar formation. Weak
expression of Osx is observed in the prehypertrophic
zone. Osx is highly expressed in bone trabeculae and in
secondary ossification centers after birth. Osx is only
expressed in cells in the bone matrix and the inner
(endosteum) and outer (periosteum) bone surfaces.
Osx is required for bone formation and osteoblast 
differentiation
It has been demonstrated that Osx is necessary for bone
formation and mineralization in vivo [3]. The Osx gene
was inactivated in the mouse embryonic stem (ES) cells
using homologous recombination to understand Osx
function. Most of the exon2 coding sequence was deleted.
As a result, the Osx gene was inactivated. Heterozygous
Osx mutant mice were normal and fertile. Homozygous
Osx mutant mice were lethal and these mice had diffi-
culty in breathing, rapidly became cyanotic, and died
within 15 min of birth. Newborn homozygous mutant
mice showed severe inward bending of forelimbs and
hindlimbs [3]. Although Osx-null embryos have normal
cartilage development, they completely lack bone forma-
tion, so neither endochondral nor intramembranous
bone formation occurs. The mesenchymal cells in Osx-
Figure1 Domain structure of osteoblast-specific transcription 
factor Osx. The DNA-binding domain of Osx is located at its C termi-
nus containing three Z-finger domains and there is a proline-rich re-
gion (PRR) close to N terminus in Osx.
 Table 1: Transcription factors and mouse models associated with osteoblast differentiation
Gene Phenotype on osteoblasts (OB) in knock-out mice Role citation
Ihh reduced chondrocyte proliferation, maturation of 
chondrocytes at inappropriate position, and failure of 
OB development in endochondral bones
required for endochondral but not for 
intramembranous bone formation
1
Runx2 devoid of OB and impaired chondrocyte 
differentiation
required for OB differentiation of mesenchymal 
cells into preosteoblasts
2
Osx completely lack bone formation and cartilage is 
normal
required for differentiation of preosteoblasts into 
mature OB
3
β-catenin block OB differentiation and develop into 
chondrocyte
important for OB differentiation, and prevent 
transdifferentiation of OB into chondrocyte
4-7
Twist1 leads to premature OB differentiation antiosteogenic function by inhibiting Runx2 
function during skeletogenesis
8
ATF4 delayed bone formation during embryonic 
development and low bone mass throughout 
postnatal life
critical regulator of OB differentiation and 
function
9
SatB2 both craniofacial abnormalities and defects in OB 
differentiation and function
a molecular node in a transcriptional network 
regulating skeletal development and OB 
differentiation
10
Shn3 adult-onset osteosclerosis with increased bone mass 
due to augmented OB activity
a central regulator of postnatal bone mass 11
Dlx5 delayed ossification of the roof of the skull and 
abnormal osteogenesis
positive regulator in OB differentiation 12
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periosteum and the condensed mesenchyme of membra-
nous skeletal elements cannot differentiate into osteo-
blasts. In the endochondral skeletal elements of Osx-null
mutants, a dense mesenchyme emerges from the per-
ichondrium/periosteum and invades the zone of hyper-
trophic chondrocytes along with blood vessels. However,
cells in this mesenchyme are arrested during differentia-
tion. A similar, dense mesenchyme is also found in the
membranous skeletal elements. Bone trabeculae are com-
pletely absent in all skeletal elements. Although mineral-
ization does not occur in membranous skeletal elements,
it does in the endochondral skeleton because of the phys-
iological mineralization of the zone of hypertrophic
chondrocytes. No mineralization occurs in the perios-
teum, suggesting that bone collars do not form.
In Osx-null mutant embryos, expression of type I colla-
gen (Col1a1) in the condensed mesenchyme of the mem-
branous skeleton and the periosteum and mesenchyme of
the endochondral skeleton is severely reduced. Expres-
sions of the osteoblast-specific markers such as osteonec-
tin, osteopontin and bone sialoprotein (BSP) cannot be
detected in these mesenchymes. In E18.5 Osx-null
embryos, osteocalcin, a late, highly specific osteoblast
marker, is not expressed in endochondral and membra-
nous skeletal elements. Despite a lack of osteoblast mark-
ers expression, Runx2 expression in Osx-null mutants
remains comparable to that of wild-type osteoblasts in
the dense mesenchyme of both membranous and endo-
chondral skeletal elements. Thus, osteoblast differentia-
tion is completely arrested in Osx-null embryos, even
though similar expression of Runx2 remains compared to
wild-type embryos. On other hand, over-expressed Osx
in vitro has been shown to induce expression of osteocal-
cin and collagen type 1a1.
In the skeletal elements of E18.5 Osx-null embryos the
number of TRAP-positive cells appear to be reduced
compared to wild-type embryos. In long bones of Osx-
null embryos cells from the periosteum invade the zone
of the hypertrophy chondrocyte as a wedge-shaped
expansion of the periosteum in which osteoblast precur-
sors are arrested in their differentiation. These observa-
tions are supported by the evidence that expressions of
both OPG and RANKL are downregulated, but the ratio
of OPG/RANKL increases in E18.5 Osx-null calvarial
cells [13]. Expression of the osteoclast marker TRAP is
also downregulated. Thus, it is possible that the inhibi-
tion of Wnt signaling by Osx also reduces osteoclast dif-
ferentiation and function. It is speculated that the
inhibition of Wnt signaling by Osx, which itself has an
essential role in osteoblast differentiation, insures an
optimal bone formation rate.
Osx inhibits osteoblast proliferation during bone 
development
It has been demonstrated that canonical Wnt signaling is
required for normal osteoblast proliferation. A marked
increase in osteoblast proliferation occurs when β-
catenin is stabilized in osteoblasts during mouse embry-
onic development [6]. Moreover Lrp5-null mice, which
phenocopy the osteoporosis-pseudoglioma syndrome in
humans [14], develop a phenotype with low bone mass
due to decreased osteoblast proliferation [15]. In con-
trast, gain-of-function mutants of Lrp5 lead to high bone
mass syndrome in patients [16] and in mice [17]. The
Wnt signaling antagonist Dkk1 prevents the activation of
Wnt signaling by binding to LRP5/6. It has been shown
that the bone formation and bone mass of heterozygous
Dkk1 mutant mice increase with an increased number of
osteoblasts [18]. In contrast, the overexpression of Dkk1
in osteoblasts causes severe osteopenia with decreased
osteoblast numbers [19]. These data indicate that Wnt
signaling stimulates osteoblast proliferation.
Recent studies in our research group have provided evi-
dences showing that the osteoblast-specific transcription
factor Osx is able to inhibit Wnt pathway activity during
osteoblast differentiation [13]. In calvarial cells of E18.5
Osx-null embryos, expression of the Wnt antagonist
Dkk1 was abolished, and that of Wnt target genes c-Myc
and cyclin D1 was increased. It has been demonstrated
that Osx binds to and activates the Dkk1 promoter. Osx is
shown to inhibit β-catenin-induced Topflash reporter
activity and also inhibit β-catenin-induced secondary axis
formation in Xenopus embryos. Moreover, this study
showed that in calvaria of E18.5 Osx-null embryos har-
boring the TOPGAL reporter transgene, β-galactosidase
activity was increased, suggesting that Osx inhibited the
Wnt pathway in osteoblasts in vivo [13]. Osx can disrupt
Tcf binding to DNA, providing a likely mechanism for the
inhibition by Osx of β-catenin transcriptional activity.
The transcription factor Tcf is known to interact with β-
catenin to form a functional complex in promoter region
of Wnt signaling targets to activate gene expression.
The PRR region of Osx is responsible for disruption of
Tcf1 binding to DNA, and for inhibition of β-catenin
transcriptional activity. These findings indicate that Osx
negatively controls the activity of β-catenin in two differ-
ent mechanisms shown in Figure2: first, by being needed
for the expression of a major Wnt antagonist and second,
by inhibiting the transcriptional activity of β-catenin/Tcf.
We have shown that Osx decreases osteoblast prolifera-
tion [13]. E18.5 Osx-null calvaria showed greater BrdU
incorporation than wild-type calvaria, and primary calva-
rial cells from Osx-null E18.5 embryos also grew faster
than wild-type cells. On the other hand, Osx over-expres-
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Because Wnt signaling has a major role in stimulating
osteoblast proliferation, it is speculated that Osx-medi-
ated inhibition of osteoblast proliferation is a conse-
quence of the Osx-mediated control of Wnt/β-catenin
activity. These results add a new layer of control to Wnt
signaling in bone formation.
Molecular pathway of osteoblast differentiation
Osx is necessary for the osteoblast lineage [3,13]. Follow-
ing the lineage commitment, osteoprogenitors undergo a
proliferative stage. Subsequently, they exit mitosis, transit
to express genes such as alkaline phosphatase (ALP),
bone sialoprotein (BSP) and type I collagen, as they com-
mence to produce and mature osteogenic extracellular
matrix. Finally, they express genes involved in mineraliza-
tion of the extracellular matrix such as osteocalcin (OC),
osteopontin. This highly regulated program of gene
expression and cellular differentiation is governed by the
expression and activity of different transcription factors.
These factors do not act alone but interact with each
other to integrate diverse signals and fine-tune gene
expression.
Based on the characterization of the Osx-null mutant
phenotype and recent studies, the following brief model
for osteoblast differentiation is proposed as shown in
Figure3. Ihh is the initiator of endochondral ossification.
Osteoblast progenitors in mesenchymal condensations
differentiate first into biopotential progenitors in which
Runx2 starts to express. These Runx2-expressing biopo-
tential progenitors can differentiate into either osteoblast
or chondrocyte depending on cell signaling. Then cells
differentiate into preosteoblasts, a process in which
Runx2 play an essential role. At this stage, preosteoblasts
express early osteoblast marker genes like ALP. Next step,
preosteoblasts differentiate into mature osteoblast, a pro-
cess in which Osx plays a critical role. Mature functioning
osteoblasts strongly express characteristic later osteoblast
marker genes such as OC and BSP. In the membranous
and endochondral skeletons, Osx-null preosteoblasts are
blocked from differentiating into osteoblasts, so there is
no mature osteoblast without Osx. In Osx-null embryos,
osteoblast differentiation markers, such as OC, BSP and
osteonectin, are not expressed. Because the promoter
regions of several osteoblast marker genes contain bind-
ing sites for Runx2 that are functional in DNA transfec-
tion experiments [20,21], it is possible that the Runx2 and
other transcription factors, act with Osx to activate
osteoblast marker genes in vivo and produce a bone-spe-
cific matrix.
Wnt/β-catenin signaling has an essential role in osteo-
blast differentiation during embryonic development and
has a major role in stimulating osteoblast proliferation
during both embryonic and postnatal development. Osx
is an osteoblast-specific transcription factor, required for
osteoblast differentiation. The inhibition of Wnt/β-
catenin signaling activity by Osx, also constitutes a possi-
ble mechanism for the inhibition of osteoblast prolifera-
tion by Osx. Recent observations that Osx inhibits Wnt
signaling pathway in vitro and in vivo provide novel con-
cept of feedback control mechanisms involved in bone
formation [13].
Osx is believed to be downstream of Runx2 in the path-
way of osteoblast differentiation because Runx2 expres-
sion is normal in Osx-null mice, while no Osx transcripts
are detected in skeletal elements in Runx2-knockout mice
[3]. This is confirmed through characterization of a
Runx2-binding element in the Osx gene promoter [22]. It
is not known yet which transcription factors are down-
stream target of Osx.
Regulation of Osx expression in osteoblasts
The mechanism underlying the regulation of Osx expres-
sion in osteoblasts is still unclear. Several studies have
reported that some factors can modulate Osx expression.
Both BMP-2 and insulin-like growth factor-1 (IGF-1) can
Figure2 Model of mechanisms of the Osx inhibitory effect on Wnt 
pathway. Osx negatively controls Wnt pathway by two different 
mechanisms: activates the expression of Wnt antagonist Dkk1 and dis-
rupts Tcf binding to DNA to inhibit the transcriptional activity of β-
catenin/Tcf.
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stem cells [23]. IGF-I-mediated Osx expression required
all three MAPK components (Erk, p38, and JNK),
whereas BMP-2 required p38 and JNK signaling. Block-
ing Runx2 activity inhibited the BMP-2-mediated induc-
tion of Osx, suggesting a Runx2-dependent pathway.
However, another research group showed that BMP-2
induced Osx expression through a Runx2-independent
pathway [24]. Even if Osx has been suggested as a down-
stream target of Runx2, the results of this study indicated
that Osx expression was still induced by BMP-2 treat-
ment in Runx2 null cells but not induced by Runx2 over-
expression in C2C12 cells. Regulatory mechanisms of
BMP-2 on Osx are not yet fully understood. Ascorbic acid
and 1,25(OH)2 vitamin D3, which have positive roles in
osteoblast function, have also been shown to up-regulate
Osx expression [25,26]. It was demonstrated that Ascor-
bic acid induced Osx expression via a novel mechanism
involving Nrf1 nuclear translocation and Nrf1 binding to
an antioxidant-responsive element to activate genes criti-
cal for cell differentiation.
Some studies indicate that negative regulators of osteo-
blastogenesis can inhibit Osx expression. TNF inhibited
Osx mRNA in pre-osteoblastic cells without affecting
Osx mRNA half-life [27,28]. Inhibitors of MEK1 and
ERK1, but not of JNK or p38 kinase, abrogated TNF inhi-
bition of Osx mRNA and promoter activity. In vivo stud-
ies provide genetic evidence that p53 tumor suppressor
blocks osteoblast differentiation and bone development
[27,28]. Prolonged exposure to parathyroid hormone
(PTH) negatively regulates Osx expression in osteoblasts
by a transcriptional mechanism mediated by cAMP sig-
naling [29]. PTH inhibited Osx mRNA and protein
expression, and this effect could be mimicked by forsko-
lin, 8-bromo-cAMP, or expression of constitutively active
Gsalpha. On the other hand, some other researchers
found that systemic PTH treatments accelerated fracture
healing in mice concomitantly with increased Osx
expression in the PTH treated fracture calluses, suggest-
ing a mechanism for PTH-mediated fracture healing pos-
sibly via Osx induction [30]. Recently studies indicated
that intermittent PTH increased in vivo Osx expression
in osteoblasts through a pathway requiring activating
transcription factor 4 (ATF4) [31]. ATF4-responsive ele-
ment has been identified in the proximal Osx promoter.
Despite these interesting findings, the details concern-
ing the regulation and function of Osx are incompletely
understood.
Osteoporosis and Osx
Osteoporosis is characterized by reduced bone mass,
alterations in the microarchitecture of bone tissue,
Figure3 The proposed model of coordinated regulation of osteoblast differentiation and proliferation during bone formation by Osx and 
Wnt/β-catenin signaling. Ihh is the initiator of endochondral ossification. The Runx2-expressing biopotential progenitors can differentiate into either 
osteoblast or chondrocyte. Then cells differentiate into preosteoblasts, in which Runx2 play an essential role. In the next step, preosteoblasts differen-
tiate into mature osteoblast, a process in which Osx plays a critical role. Wnt/β-catenin signaling has an essential role in osteoblast differentiation and 
osteoblast proliferation. The inhibition of Wnt/β-catenin signaling activity by Osx constitutes a possible mechanism for the inhibition by Osx of osteo-
blast proliferation.
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[32]. Osteoporosis is a common condition that affects up
to 30% of women and 12% of men at some point in life.
The prevalence of osteoporosis increases with age due to
an imbalance in the rate at which bone is removed and
replaced during the bone remodeling, which is an impor-
tant physiological process essential for healthy skeleton
maintenance. Many factors influence the risk of osteopo-
rosis--including diet, physical activity, medication use,
and coexisting diseases--but one of the most important
clinical risk factors is a positive family history, emphasiz-
ing the importance of genetics in the pathogenesis of
osteoporosis. Genetic factors have been recognized to
play important roles in the pathogenesis of osteoporosis.
Evidence from twin and family studies suggests that
between 50% and 85% of the variance in peak bone mass
is genetically determined [33].
Recent study has indicated that genetic variants in the
chromosomal region of Osx are associated with bone
mineral density (BMD) in children and adults probably
through primary effects on growth [34]. A genome-wide
association study of BMD and related traits in 1518 chil-
dren from the Avon Longitudinal Study of Parents and
Children (ALSPAC) was carried out to identify genetic
variants affecting BMD. This research group identified
associations with BMD in an area of chromosome 12 con-
taining the Osx (SP7) locus. A meta-analysis of these
existing studies revealed strong association between
SNPs in the Osx region and adult lumbar spine BMD. In
light of these findings, this research group genotyped a
further 3692 individuals from ALSPAC who had whole
body BMD and confirmed the association in children as
well.
Although Osx has been identified to be associated with
osteoporosis-related phenotypes, further investigation
needs to be done to determine whether Osx will repre-
sent a useful diagnostic index of osteoporosis or molecu-
lar target for therapeutic manipulation.
Possible clinical application of Osx
Osx is indispensable for the commitment of the osteo-
blast lineage and the expression of the osteoblast-specific
matrix proteins, including type I collagen, bone sialopro-
tein, osteonectin, and osteocalcin. No pharmacological
approach to target Osx in osteoblasts has been reported.
Heterozygous mutations in Runx2 , which is an upstream
of Osx, have been shown to be the cause of the human
genetic disease cleidocranial dysplasia [35]. There is no
evidence so far that any Osx mutation leads to any clinical
human disease.
The extensive studies by many laboratories to explore
how to control the Wnt signaling pathway in osteoblasts
stems from the realization that this pathway has an essen-
tial role in bone mass determination in the adult skeleton.
There is also an expectation that efforts to pharmacologi-
cally target this pathway should yield promising agents to
treat bone diseases such as osteoporosis. Results in our
group showing that Osx inhibits Wnt/β-catenin signaling
add an important new layer of control to the complex
regulation of the Wnt pathway in osteoblasts [13].
It was observed that the Osx expression was decreased
in two mouse osteosarcoma cell lines and in three human
osteosarcoma cell lines [36]. Transfection of the Osx gene
into the mouse osteosarcoma cells inhibited tumor cell
growth in vitro and in vivo and significantly reduced
tumor incidence, tumor volume, and lung metastasis fol-
lowing intratibial injection. Using an in vitro migration
assay, Osx suppressed the migration of tumor cells to
lung extracts. These results suggest that Osx expression
may play a role in osteosarcoma tumor growth and
metastasis, and that osteolytic activity of tumor cells may
be regulated by Osx via down-regulation of interleukin-1
gene transcription [36]. It is relatively consistent with the
recent mechanism studies that Osx inhibits osteoblast
proliferation through controlling the Wnt pathway [13].
Bone formation is essential for maintenance and heal-
ing of the skeleton following injury and operative inter-
ventions, such as osteotomies and limb lengthening. In
numerous orthopedic conditions, such as congenital
pseudoarthrosis of tibia, femoral head osteonecrosis, and
large bone lengthening, bone healing and regeneration
remain challenging goal to achieve. Most therapy for skel-
etal diseases with less bone such as osteoporosis and
osteonecrosis is aimed at inhibiting bone resorption, but
to cure these diseases, it is also critically important to
stimulate new bone formation. Therefore, there is cur-
rently great interest in understanding the regulation of
osteoblast differentiation and activity to guide the devel-
opment of anabolic therapies. Although no pharmacolog-
ical approach to target Osx in osteoblasts has identified
yet, an interesting future research direction is to look for
upstream genes or molecules which can selectively target
Osx expression and activity. We speculate that Osx could
become a therapeutic target in efforts to stimulate the
anabolic pathway of bone synthesis.
Conclusions
Bone formation is a complex process regulated by multi-
ple factors and pathways; it is clearly shown that Osx is
required for the final commitment of osteoblast lineage.
Although recent molecular and genetic studies using
gene targeting in mice have established Osx as a master
regulator of osteoblast differentiation during bone forma-
tion, the mechanisms of Osx regulation of osteoblast dif-
ferentiation and function are still under investigation.
Future studies to decipher the Osx direct upstream or
downstream molecular targets, Osx expression regula-
tion and Osx functional partners are required to clarify
Zhang Journal of Orthopaedic Surgery and Research 2010, 5:37
http://www.josr-online.com/content/5/1/37
Page 7 of 8the detailed mechanism of the temporal and spatial regu-
lation of Osx for bone formation and homeostatic regula-
tion of skeletal system. The need to develop novel drugs
that stimulate bone formation and thereby elevate bone
mass (anabolic agents) has opened new research areas for
therapeutic intervention in the treatment of bone-related
diseases.
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